USPTO serial 97473476
X SCRIBE THERAPEUTICS
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- DIBLE,JONATHON I
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with X SCRIBE THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $324*
Plus Government fees of $125
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Paul Oleksiuk
John Paul Oleksiuk COOLEY LLP1299 PENNSYLVANIA AVENUE, NW, SUITE 700WASHINGTON, DC 20004United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cance | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 15, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 15, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Dec 14, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Dec 14, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 9, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 9, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 18, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 18, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 2, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Dec 16, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 16, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 15, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 11, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 11, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 11, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 12, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 10, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 10, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 10, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 20, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 25, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 25, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 16, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 16, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 16, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 16, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 16, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 9, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 13, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 12, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 27, 2022 | NWAP | NEW APPLICATION ENTERED | — |